Health-related quality of life in individuals with syndromic autism spectrum disorders

Corneliu Bolbocean; Fabiola N. Andújar; Maria McCormack; Bernhard Suter; J. Lloyd Holder

doi:10.1101/2020.06.10.20127951

ABSTRACT

BACKGROUND Children with autism have a significantly lower quality of life compared with their neurotypical peers. While multiple studies have quantified the impact of autism on health-related quality of life (HRQoL) through standardized surveys such as the PedsQL, none have specifically investigated the impact of syndromic autism spectrum disorder on children’s HRQoL or on family quality of life. Here we evaluate HRQoL in children diagnosed with three syndromic Autism Spectrum Disorders (ASDs): Phelan-McDermid syndrome (PMD), Rett syndrome (RTT), and SYNGAP1-related intellectual disability (SYNGAP1-ID).

METHODS A standardized online Pediatric Quality of Life Inventory (PedsQL 4.0) survey and the Beach Center Family Quality of Life Scale (FQOL) were administered to caregivers of children with PMD (n= 213), RTT (n= 148), and SYNGAP1-ID (n= 30). The PedsQL 4.0 measures health-related quality of life in four dimensions: physical, emotional, social and school. The Beach Center Family Quality of Life Scale measures five dimensions: family interaction, parenting, emotional well-being, physical/material well-being and disability-related support.

RESULTS For the PedsQL, the most severely impacted dimension in children with syndromic autism was physical functioning. In comparing individual dimensions among the genetically-defined syndromic autisms, individuals with RTT had significantly worse physical functioning, emotional and school scores than PMD. This finding is congruent with the physical regression typically associated with Rett syndrome. Strikingly, syndromic autism results in worse quality of life than other chronic disorders including idiopathic autism.

CONCLUSIONS The reduced HRQoL for children with syndromic autism spectrum disorders relative to other chronic childhood illnesses, likely reflects their lack of targeted therapies. This study demonstrates the utility of caregiver surveys in prioritizing phenotypes, which may be targeted as clinical endpoints for genetically defined ASDs.

CONTRIBUTORS’ STATEMENT Dr. Bolbocean conceptualized and designed the study, designed the data collection instrument, collected data, performed data analysis, wrote and edited the manuscript.

Ms. Andujar performed initial data analysis, drafted the initial manuscript and edited the manuscript.

Ms. McCormack performed data analysis and edited the manuscript.

Dr. Suter conceptualized and designed the study and made critical edits to the manuscript.

Dr. Holder conceptualized and designed the study, designed the data collection instrument, performed data analysis, wrote and edited the manuscript.

Table of contents summary In this study, we determine the impact of genetically-defined syndromic autism spectrum disorders on their health-related quality of life.

What’s known on this subject Children with neurodevelopmental disorders, including autism, have severely impaired health-related quality of life. Systematic measurement of HRQoL in children with neurodevelopmental disorders through standardized instruments provides a holistic understanding of disease impact and therapeutic endpoint for clinical trials.

What this study adds This study defines the impact of three genetically defined autism spectrum disorders: Rett syndrome, Phelan-McDermid syndrome and SYNGAP1-related Intellectual Disability, on health-related quality of life. We find significantly greater impairment for syndromic ASDs than other neurodevelopmental disorders.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the Robbins Foundation (to Drs. Bolbocean and Holder). Dr. Holder is also generously supported by the Joan and Stanford Alexander Endowed Chair and Mr. Charif Souki.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Baylor College of Medicine Institutional Review Board approved this work.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Funding source: This study was supported by the Robbins Foundation (to Drs. Bolbocean and Holder). Dr. Holder is also generously supported by the Joan and Stanford Alexander Endowed Chair and Mr. Charif Souki.
Financial disclosure: All authors have indicated they have no financial relationships relevant to this article.
Conflict of interest: All authors have no potential conflicts of interest to disclose.